Patient journey in HR+, HER2– breast cancer
The patient journey in HR+, HER2– BC is guided by many factors including disease stage, tumour biology and evolution, treatment response and tolerability.1–4

You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.